ESCUDDO trial finds single-dose HPV vaccination noninferior to two doses

The issue: Current guidelines recommend two doses of Gardasil 9 for adolescents; whether one dose provides comparable protection has been uncertain.

Why this study matters: The ESCUDDO trial randomized girls 12 to 16 years to one or two doses of bivalent (Cervarix) or nonavalent (Gardasil 9) HPV vaccine; one dose was noninferior to two doses for preventing HPV16 or HPV18 infection.

Primary care relevance: Supports WHO single-dose recommendation; study has limitations including 5-year follow-up and nonrandomized control group requiring propensity matching.

Recent studies show benefit in severe disease, but routine use remains unproven

The issue: Studies evaluating corticosteroids in CAP have produced mixed results; their role in routine practice is uncertain.

Why these studies matter: The SONIA trial showed reduced mortality with glucocorticoids in low-resource settings; the CAPE COD trial showed benefit in ICU patients.

Primary care relevance: The IDSA recommends against routine steroids in CAP; evidence supports use only in severely ill patients requiring ICU care.

Zoliflodacin and gepotidacin offer oral alternatives to injectable ceftriaxone

The issue: Gonorrhea resistance to current therapies is increasing.

Primary care relevance: Providers now have two new oral antibiotics to treat gonorrhea, potentially improving treatment access and patient convenience.

Retreatment reduces viral loads and symptoms by one day but shows no meaningful benefit on hospitalizations or deaths

The issue: Some patients experience COVID symptom rebound after completing Paxlovid; the safety and benefit of retreatment have not been studied.

Why this study matters: This study evaluated the safety and benefits of a second course of Paxlovid in patients with rebound COVID symptoms.

Primary care relevance: Provides guidance on whether to retreat COVID-19 patients experiencing rebound symptoms.

Combined oral and topical therapy in male partners significantly reduces BV recurrence in females

The issue: Bacterial vaginosis recurrence is common; the role of partner treatment has been debated.

Why this study matters: Randomized controlled trial evaluating the effects of treating male partners of women with recurrent bacterial vaginosis.

Primary care relevance: Provides evidence on the benefits of treating male partners of women with recurrent bacterial vaginosis.

New antibiotic for uncomplicated female UTIs; also shows efficacy against gonorrhea

The issue: Resistance and limited oral options complicate treatment of uncomplicated UTIs and gonorrhea.

Primary care relevance: Providers have a new oral antibiotic for female UTIs; it may also be useful for gonorrhea in appropriate settings.

Sulopenem plus probenecid (Orlynvah) approved for uncomplicated UTIs in women

The issue: Multidrug-resistant uropathogens and limited oral options make UTI treatment challenging.

Primary care relevance: A new oral option for UTIs; consider cost and resistance patterns when selecting therapy.

Review of pneumococcal vaccines including efficacy in clinical trials

The issue: Pneumococcal vaccination is widely recommended, but the evidence supporting its effectiveness is limited.

Primary care relevance: Review of pneumococcal vaccines and their efficacy in clinical trials.